|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5344760A
(en)
|
1991-06-03 |
1994-09-06 |
Ciba Corning Diagnostics Corp. |
Method of cancer detection
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6983227B1
(en)
|
1995-01-17 |
2006-01-03 |
Intertech Ventures, Ltd. |
Virtual models of complex systems
|
|
CA2245835A1
(en)
|
1995-06-14 |
1997-01-03 |
The Regents Of The University Of California |
Novel high affinity human antibodies to tumor antigens
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
IL126303A
(en)
|
1996-03-27 |
2002-05-23 |
Genentech Inc |
ErbB3 ANTIBODIES
|
|
WO1998002540A1
(en)
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
GB2336695A
(en)
|
1998-04-20 |
1999-10-27 |
Teamware Group Oy |
Modelling a work process
|
|
KR20010071271A
(ko)
|
1998-05-15 |
2001-07-28 |
존 비. 랜디스 |
방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20020009740A1
(en)
|
2000-04-14 |
2002-01-24 |
Rima Kaddurah-Daouk |
Methods for drug discovery, disease treatment, and diagnosis using metabolomics
|
|
KR20130056201A
(ko)
|
2000-05-19 |
2013-05-29 |
제넨테크, 인크. |
ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
US6871171B1
(en)
|
2000-10-19 |
2005-03-22 |
Optimata Ltd. |
System and methods for optimized drug delivery and progression of diseased and normal cells
|
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
EP1392359B2
(en)
*
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
|
US7612042B2
(en)
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
|
US7125680B2
(en)
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
|
JP2005508887A
(ja)
|
2001-08-03 |
2005-04-07 |
コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション |
Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法
|
|
AU2002326531A1
(en)
|
2001-08-03 |
2003-02-17 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
BR0213424A
(pt)
|
2001-10-19 |
2004-12-14 |
Pharma Mar Sa |
Uso aperfeiçoado de composto antitumoral na terapia contra câncer
|
|
US7415359B2
(en)
|
2001-11-02 |
2008-08-19 |
Gene Network Sciences, Inc. |
Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
|
|
EP2400021B1
(en)
|
2002-03-26 |
2016-11-30 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
ErbB3 based methods and compositions for treating neoplasms
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
|
AU2003251597A1
(en)
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
ES2263984T3
(es)
|
2002-06-28 |
2006-12-16 |
Domantis Limited |
Ligandos doble-especificos con una vida media serica aumentada.
|
|
ES2246191T1
(es)
|
2002-12-11 |
2006-02-16 |
Ventana Medical Systems, Inc. |
Metodo para predecir la respuesta a la terapia dirigida a her2.
|
|
CA2521077A1
(en)
|
2003-04-01 |
2004-10-28 |
Monogram Biosciences, Inc. |
Erbb surface receptor complexes as biomarkers
|
|
US20050079184A1
(en)
|
2003-08-08 |
2005-04-14 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
WO2005017493A2
(en)
|
2003-08-15 |
2005-02-24 |
Smithkline Beecham Corporation |
Biomarkers in cancer
|
|
US8554486B2
(en)
|
2004-02-20 |
2013-10-08 |
The Mathworks, Inc. |
Method, computer program product, and apparatus for selective memory restoration of a simulation
|
|
CN101501211A
(zh)
|
2004-03-31 |
2009-08-05 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
|
CN1997382A
(zh)
|
2004-05-05 |
2007-07-11 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
|
WO2005117553A2
(en)
|
2004-05-27 |
2005-12-15 |
The Regents Of The University Of Colorado |
Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
|
|
US7794960B2
(en)
|
2004-06-04 |
2010-09-14 |
Glaxosmithkline Llc |
Predictive biomarkers in cancer therapy
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
PL1774037T3
(pl)
|
2004-08-06 |
2011-09-30 |
Genentech Inc |
Oznaczenia i sposoby wykorzystujące biomarkery
|
|
JP2008532476A
(ja)
|
2004-08-12 |
2008-08-21 |
ダイアックス コーポレーション |
複合結合タンパク質
|
|
WO2006044378A2
(en)
|
2004-10-12 |
2006-04-27 |
University Of Iowa Research Foundation |
Rapid computational identification of targets
|
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
|
JP2008523073A
(ja)
|
2004-12-07 |
2008-07-03 |
ジェネンテック・インコーポレーテッド |
Ｈｅｒ阻害剤を用いた治療のための患者の選択
|
|
US7862995B2
(en)
|
2004-12-10 |
2011-01-04 |
Targeted Molecular Diagnostics |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
|
|
CA2599606A1
(en)
|
2005-02-23 |
2006-08-31 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
WO2006096861A2
(en)
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
|
US20090061422A1
(en)
|
2005-04-19 |
2009-03-05 |
Linke Steven P |
Diagnostic markers of breast cancer treatment and progression and methods of use thereof
|
|
EP1913160A2
(en)
|
2005-07-29 |
2008-04-23 |
Bayer Healthcare LLC |
Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
|
|
WO2007041502A2
(en)
|
2005-09-30 |
2007-04-12 |
Monogram Biosciences |
Methods for determining responsiveness to cancer therapy
|
|
EP1931798A1
(en)
|
2005-10-05 |
2008-06-18 |
AstraZeneca UK Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7908091B2
(en)
|
2006-03-17 |
2011-03-15 |
Prometheus Laboratories Inc. |
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
|
|
WO2007115571A2
(en)
|
2006-04-07 |
2007-10-18 |
Enkam Pharmaceuticals A/S |
Erbb receptor-derived peptide fragments
|
|
WO2007130677A2
(en)
|
2006-05-05 |
2007-11-15 |
Yale University |
Use of subcellular localization profiles as prognostic or predictive indicators
|
|
US7709222B2
(en)
|
2006-07-13 |
2010-05-04 |
Yale University |
Methods for making cancer prognoses based on subcellular localization of biomarkers
|
|
EP2062597A4
(en)
*
|
2006-09-15 |
2010-03-03 |
Univ Tokai |
PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR
|
|
WO2008073629A2
(en)
|
2006-11-03 |
2008-06-19 |
Board Of Regents, The University Of Texas System |
Bifunctional predictors of cancer treatment sensitivity and resistance
|
|
JP5656406B2
(ja)
|
2006-11-28 |
2015-01-21 |
ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ |
治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
|
|
US7825127B2
(en)
|
2006-12-28 |
2010-11-02 |
Takeda Pharmaceutical Company, Limited |
Method for treating cancer
|
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
NZ581201A
(en)
|
2007-05-11 |
2012-05-25 |
Enzon Pharmaceuticals Inc |
Rna antagonist compounds for the modulation of her3
|
|
US20090054051A1
(en)
|
2007-08-22 |
2009-02-26 |
James Cavallo |
Attachable Headset for Portable Device
|
|
CA2721093A1
(en)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
UA104868C2
(uk)
|
2008-08-15 |
2014-03-25 |
Меррімак Фармасьютікалз, Інк. |
Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
JP5752687B2
(ja)
|
2009-08-21 |
2015-07-22 |
メリマック ファーマシューティカルズ インコーポレーティッド |
Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用
|
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
CA2792327C
(en)
|
2010-03-11 |
2019-09-24 |
Merrimack Pharmaceuticals, Inc. |
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
US8877687B2
(en)
|
2010-04-26 |
2014-11-04 |
Merrimack Pharmaceuticals |
Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
|
|
EP2590654B1
(en)
|
2010-07-09 |
2016-12-21 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
|
FR2963868B1
(fr)
|
2010-08-11 |
2012-09-28 |
Valeo Systemes Thermiques |
Echangeur de chaleur comprenant un element chauffant serigraphie
|
|
AU2011341337A1
(en)
|
2010-12-10 |
2013-06-13 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of bispecific scFv conjugates
|
|
EP2678359A4
(en)
|
2011-02-24 |
2015-01-28 |
Merrimack Pharmaceuticals Inc |
COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM
|
|
US20140134170A1
(en)
*
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
SG192775A1
(en)
|
2011-03-15 |
2013-09-30 |
Merrimack Pharmaceuticals Inc |
Overcoming resistance to erbb pathway inhibitors
|
|
CN105884900A
(zh)
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
|
CN103596592A
(zh)
|
2011-05-06 |
2014-02-19 |
梅里麦克制药股份有限公司 |
用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
|
|
AU2012273361A1
(en)
|
2011-06-24 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
|
|
EP2726100A4
(en)
|
2011-06-30 |
2015-04-29 |
Merrimack Pharmaceuticals Inc |
ANTIBODIES TO ERBB3 IN COMBINATION WITH PACLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL CANCER TYPES
|
|
AU2012294326A1
(en)
*
|
2011-08-10 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
|
|
BR112014024494A2
(pt)
|
2012-04-02 |
2017-08-08 |
Merrimack Pharmaceuticals Inc |
dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
CA2975829A1
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|